PMA device
SAPIEN M3 Transcatheter Mitral Valve Replacement System
Edwards Lifesciences, LLC · Prosthesis, Mitral Valve, Percutaneously Delivered (NPU, Class III) · First FDA decision Dec 22, 2025, newest Feb 19, 2026Mitral regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
2
Naming "SAPIEN M3"
MAUDE reports
185
Brand "SAPIEN M3", since 2015
PubMed studies
16
Mentioning "SAPIEN M3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SAPIEN M3 Transcatheter Mitral Valve Replacement System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- SAPIEN M3 Transcatheter Mitral Valve Replacement SystemPMA supplement
P250019-S001 · Decided Feb 19, 2026 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Prosthesis, mitral valve, percutaneously delivered (NPU) · Cardiology
- SAPIEN M3 Transcatheter Mitral Valve Replacement SystemBreakthroughPMA
P250019 · Decided Dec 22, 2025 · 180 days after receipt
Device type: Prosthesis, mitral valve, percutaneously delivered (NPU) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Edge-to-Edge Repair (TEER) for Mitral Valve RegurgitationNational analysisReview closedCAG-00438RUpdated Sep 23, 2026
- Transcatheter Mitral Valve Repair (TMVR)National analysisReview closedCAG-00438RUpdated Sep 23, 2026
- Transcatheter Mitral Valve Repair (TMVR)National analysisReview closedCAG-00438NUpdated Sep 23, 2026
- Transcatheter Edge-to-Edge Repair (TEER) for Mitral Valve RegurgitationNational determinationOn the books20.33Updated Aug 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "SAPIEN M3", any status and sponsor, newest update first.
- The ENCIRCLE TrialActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT04153292 · 786 participants · Start Nov 12, 2020 · Primary completion Oct 10, 2027
Device: SAPIEN M3 valve and dock · For: Mitral Regurgitation; Mitral Valve Insufficiency
Sites: Huntsville, Alabama; Phoenix, Arizona; La Jolla, California · 54 sites in all
Edwards LifesciencesPublic (EW)
NCT03230747 · 72 participants · Start Sep 14, 2017 · Primary completion Jun 16, 2021
Device: Edwards SAPIEN M3 System · For: Mitral Regurgitation; Mitral Disease
Sites: Los Angeles, California; San Francisco, California; Atlanta, Georgia · 9 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SAPIEN M3", and for the whole product code for context.
This brand
185 reports: 1 malfunction, 169 injury, 15 death
Whole product code NPU
2,081 reports: 149 malfunction, 1,500 injury, 432 death
Newest reports for this brand
2015691-2026-19845 · Received Oct 29, 2026 · Event dated Oct 14, 2026
Device type: Prosthesis, Mitral Valve, Percutaneously Delivered (NPU)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Cardiac Perforation
2015691-2026-19797 · Received Oct 28, 2026 · Event dated Oct 8, 2026
Device type: Prosthesis, Mitral Valve, Percutaneously Delivered (NPU)
Device problem as coded: Perivalvular Leak
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2015691-2026-19798 · Received Oct 28, 2026 · Event dated Oct 9, 2026
Device type: Prosthesis, Mitral Valve, Percutaneously Delivered (NPU)
Device problem as coded: Malposition of Device
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0287-2027 · Started Oct 5, 2026 · Posted by FDA Nov 2, 2026
Reason given: Due to a manufacturing issue which may result in cardiovascular balloon rupturing.
Cause as FDA categorized it: Process change control · Device type: Prosthesis, Mitral Valve, Percutaneously Delivered (NPU)
Published research
The most relevant PubMed records for "SAPIEN M3"[tiab]. The summary above synthesizes these.
- Transcatheter Mitral Valve Replacement: 5 Years Later.
Husain A, Meier D, Dundas J, et al. · JACC Cardiovasc Interv · 2023Research Support, Non-U.S. Gov't
- The SAPIEN M3 system for transcatheter mitral valve replacement: A new era begins.
Penteris M, Lampropoulos K · Cardiovasc Revasc Med · 2025Review
- Treatment of Acute M3 Thrombosis.
Syed BH, Pink K, Sunner GK, et al. · JACC Case Rep · 2026Case Reports
- Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.
Guerrero ME, Daniels DV, Makkar RR, et al. · Lancet · 2025Multicenter Study, Clinical Trial
- Transseptal Transcatheter Mitral Valve Replacement for Mitral Annular Calcification: ENCIRCLE MAC Registry 1-Year Outcomes.
Guerrero ME, Daniels DV, Whisenant B, et al. · J Am Coll Cardiol · 2026Multicenter Study, Observational Study
- Management strategies and prognosis of patients ineligible for transcatheter mitral valve replacement.
Hasan SA, Morsi M, Frakes BS, et al. · Cardiovasc Revasc Med · 2024
- Transcatheter Electrosurgical Laceration and Stabilization of Failed MitraClip[s]/SAPIEN M3 for Treatment of Failed MitraClip.
Inci EK, Greenbaum AB, Lederman RJ, et al. · Circ Cardiovasc Interv · 2022Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural
- Current Practices and Considerations for Transcatheter Mitral Valve Implantation Based on Risk Stratification Among Patients with Mitral Valve Regurgitation.
Yasmin F, Najeeb H, Fareed Siddiqui H, et al. · Curr Probl Cardiol · 2023Review
- Preventing 'dock drop' during transcatheter mitral valve replacement with the SAPIEN M3 system.
Palaparti R, Demirel C, Nitsche C, et al. · Eur Heart J Valvular Struct Heart Dis · 2026
- First Reported Native Transcatheter Tricuspid Valve Replacement in Congenitally Corrected Transposition of the Great Arteries.
D'Angelo JT, Sud K, Shekiladze N, et al. · JACC Case Rep · 2026Case Reports
- ELASTACLIP and TMVR for Failed TEER With Leaflet Tear.
Gamal A, Almalki Y, Attumalil T, et al. · JACC Case Rep · 2026Case Reports
- Double Transeptal Puncture for SAPIEN M3 Transcatheter Mitral Valve Replacement: Initial Experience, Indications, and Technique.
Fernandez-Cordon C, Hoare D, Singal A, et al. · Catheter Cardiovasc Interv · 2026
Other devices of this type
Also filed under product code NPU.
- Tendyne Transcatheter Mitral Valve SystemAbbott Medical · PMA 2025
- Edwards SAPIEN 3Edwards Lifesciences, LLC · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.